FY2018 Earnings Forecast for Urogen Pharma Ltd Issued By Oppenheimer (URGN)

Urogen Pharma Ltd (NASDAQ:URGN) – Stock analysts at Oppenheimer dropped their FY2018 earnings per share estimates for shares of Urogen Pharma in a research note issued on Tuesday, November 13th. Oppenheimer analyst L. Gershell now forecasts that the company will post earnings of ($4.61) per share for the year, down from their previous estimate of ($4.32). Oppenheimer has a “Buy” rating and a $75.00 price objective on the stock. Oppenheimer also issued estimates for Urogen Pharma’s Q4 2018 earnings at ($1.30) EPS, Q1 2019 earnings at ($1.30) EPS, Q2 2019 earnings at ($1.34) EPS, Q3 2019 earnings at ($1.49) EPS, Q4 2019 earnings at ($1.64) EPS, FY2019 earnings at ($5.77) EPS, FY2020 earnings at ($1.68) EPS, FY2021 earnings at $2.91 EPS and FY2022 earnings at $9.44 EPS.

Urogen Pharma (NASDAQ:URGN) last released its earnings results on Thursday, November 15th. The company reported ($1.28) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($1.09) by ($0.19). The business had revenue of $0.28 million for the quarter. Urogen Pharma had a negative net margin of 4,296.08% and a negative return on equity of 61.30%.

Several other brokerages have also recently issued reports on URGN. Jefferies Financial Group began coverage on Urogen Pharma in a research note on Thursday, November 8th. They set a “buy” rating and a $77.00 price objective on the stock. Stifel Nicolaus began coverage on Urogen Pharma in a research note on Thursday, September 13th. They set a “buy” rating and a $70.00 price objective on the stock. Zacks Investment Research cut Urogen Pharma from a “hold” rating to a “sell” rating in a research note on Wednesday, October 17th. Finally, Cowen restated a “buy” rating on shares of Urogen Pharma in a research note on Tuesday, August 14th. One research analyst has rated the stock with a sell rating and eight have given a buy rating to the stock. The company presently has an average rating of “Buy” and an average target price of $71.75.

Shares of URGN opened at $47.12 on Thursday. Urogen Pharma has a 12-month low of $36.66 and a 12-month high of $69.57. The firm has a market cap of $646.32 million, a P/E ratio of -22.02 and a beta of 2.39.

A number of institutional investors and hedge funds have recently made changes to their positions in the stock. Menora Mivtachim Holdings LTD. lifted its stake in Urogen Pharma by 22.2% during the second quarter. Menora Mivtachim Holdings LTD. now owns 2,499,870 shares of the company’s stock worth $124,394,000 after purchasing an additional 454,241 shares during the last quarter. Credit Suisse AG lifted its stake in Urogen Pharma by 53.1% during the third quarter. Credit Suisse AG now owns 419,828 shares of the company’s stock worth $19,828,000 after purchasing an additional 145,627 shares during the last quarter. Citadel Advisors LLC lifted its stake in Urogen Pharma by 16.6% during the third quarter. Citadel Advisors LLC now owns 374,234 shares of the company’s stock worth $17,676,000 after purchasing an additional 53,200 shares during the last quarter. Clal Insurance Enterprises Holdings Ltd lifted its stake in Urogen Pharma by 9.3% during the second quarter. Clal Insurance Enterprises Holdings Ltd now owns 310,000 shares of the company’s stock worth $15,426,000 after purchasing an additional 26,500 shares during the last quarter. Finally, Wildcat Capital Management LLC lifted its stake in Urogen Pharma by 38.4% during the second quarter. Wildcat Capital Management LLC now owns 251,459 shares of the company’s stock worth $12,513,000 after purchasing an additional 69,757 shares during the last quarter. Hedge funds and other institutional investors own 70.31% of the company’s stock.

About Urogen Pharma

UroGen Pharma Ltd., a clinical stage biopharmaceutical company, focuses on developing novel therapies for urological pathologies. Its lead product candidates, MitoGel and VesiGel are proprietary formulations of the chemotherapy drug Mitomycin C, a generic drug, which is currently used off-label for urothelial cancer treatment in a water-based formulation as an adjuvant or supplemental in post-surgery therapy.

Read More: NASDAQ

Earnings History and Estimates for Urogen Pharma (NASDAQ:URGN)

Receive News & Ratings for Urogen Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Urogen Pharma and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply